We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

82 hedge funds and large institutions have $544M invested in TCR2 Therapeutics Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 6

200% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 12

132% more capital invested

Capital invested by funds: $234M → $544M (+$310M)

28% more funds holding

Funds holding: 64 → 82 (+18)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

52% less call options, than puts

Call options by funds: $708K | Put options by funds: $1.47M

Holders
82
Holders Change
+18
Holders Change %
+28.13%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
24
Increased
36
Reduced
12
Closed
6
Calls
$708K
Puts
$1.47M
Net Calls
-$765K
Net Calls Change
-$1.4M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$35M
2
CCM
Consonance Capital Management
New York
+$26.5M
3
DM
Deerfield Management
New York
+$21.1M
4
RG
Redmile Group
California
+$18.1M
5
BlackRock
BlackRock
New York
+$17.8M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$2.39M
2
ACH
ArrowMark Colorado Holdings
Colorado
-$2.36M
3
GPCM
Granite Point Capital Management
Massachusetts
-$878K
4
DCM
DAFNA Capital Management
California
-$709K
5
ECM
Endurant Capital Management
California
-$591K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$3.23M +$1.07M +61,159 +63%
Victory Capital Management
27
Victory Capital Management
Texas
$2.8M +$953K +54,266 +65%
BBA
28
Baker Bros. Advisors
New York
$2.49M +$2.15M +122,532 New
N
29
Nuveen
North Carolina
$2.28M +$559K +31,843 +40%
SW
30
SVB Wealth
Massachusetts
$1.66M – – –
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.58M +$405K +23,086 +42%
Renaissance Technologies
32
Renaissance Technologies
New York
$1.38M +$590K +33,600 +99%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$1.17M +$431K +24,542 +74%
PPA
34
Parametric Portfolio Associates
Washington
$1.16M +$93.4K +5,318 +10%
Canada Pension Plan Investment Board
35
Canada Pension Plan Investment Board
Ontario, Canada
$1.12M +$966K +55,000 New
GPCM
36
Granite Point Capital Management
Massachusetts
$1.02M -$878K -50,000 -50%
AI
37
Atom Investors
Texas
$1.01M +$871K +49,634 New
Goldman Sachs
38
Goldman Sachs
New York
$962K +$539K +30,684 +184%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$926K +$802K +45,691 New
Invesco
40
Invesco
Georgia
$907K +$57K +3,246 +8%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$884K +$764K +43,500 New
California State Teachers Retirement System (CalSTRS)
42
California State Teachers Retirement System (CalSTRS)
California
$781K +$244K +13,887 +57%
Jacobs Levy Equity Management
43
Jacobs Levy Equity Management
New Jersey
$727K -$107K -6,105 -15%
Wells Fargo
44
Wells Fargo
California
$682K -$307K -17,479 -34%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$619K +$144K +8,191 +37%
Citadel Advisors
46
Citadel Advisors
Florida
$520K +$449K +25,582 New
IA
47
IndexIQ Advisors
New York
$493K +$23.1K +1,316 +6%
Massachusetts Financial Services
48
Massachusetts Financial Services
Massachusetts
$462K +$400K +22,755 New
TRCT
49
Tower Research Capital (TRC)
New York
$376K +$281K +16,029 +641%
Ameriprise
50
Ameriprise
Minnesota
$340K +$73K +4,155 +33%
1
2
3 4

TCRR Hedge Fund Activity: Q3 2020 in Review

82 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q3 2020, worth a combined $544M — up 132% from $234M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new TCRR positions and 6 closed out — a net gain of 18 holders — while 36 added to existing stakes and 12 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $35M. The largest seller was Morgan Stanley, cutting an estimated $2.39M.

  • 82 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q3 2020, up from 64 in Q2 2020.
  • Funds reported $544M of TCR2 Therapeutics Inc. Common Stock stock for Q3 2020, up 132% quarter-over-quarter.
  • 24 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q3 2020 and 6 closed out, a net change of +18 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q3 2020 was Wellington Management Group, an estimated $35M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q3 2020 was Morgan Stanley, an estimated $2.39M sold.

Based on aggregated 13F filings for Q3 2020.